SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT06622005 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: Cxcr1/2 Inhibitor SX-682
DRUG: Daratumumab and Recombinant Human Hyaluronidase
DRUG: Carfilzomib
DRUG: Dexamethasone
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Echocardiography
PROCEDURE: Positron Emission Tomography
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

Roswell Park Cancer Institute